Researchers have carried out an in-depth analysis of 10,478 cancer genomes across 35 different cancer types, identifying 330 ...

Bianca Muñiz, a three-time cancer survivor first diagnosed at age 11, shared her powerful story on International Childhood ...

A Northern Ireland woman, who received a shock diagnosis of ovarian cancer, is pleading with our political leaders to fund an ...

THEO-260 is a mechanistically novel oncolytic immunotherapy developed to tackle the stromal rich tumour microenvironment (TME) evident in advanced ovarian cancer and other solid tumours. Suitable for ...

The study found a significant association between higher levels of airborne pollutant particles in a person's ZIP code and ...

Oncologists caution that at-home genetic tests taken up by millions of Americans looking to gauge their cancer risk are not ...

A Co Down woman, who received a shock diagnosis of ovarian cancer at just 55 years old, is pleading with Northern Ireland ...

Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...